In light of increasing GLP-1RA use and these significant knowledge gaps, we conducted a structured literature search in March 2024 using the terms “GLP-1 receptor agonists” AND “inflammatory bowel disease” OR “ulcerative colitis” OR “Crohn’s disease.” This narrative review is, to our knowledge, the first to comprehensively explore the pathophysiological rationale, pre-clinical evidence, and clinical considerations of GLP-1RA use in IBD. Here, GLP1R is linked to inflammatory bowel disease.